We respond to NICE’s final guidance recommending the use of three tumour profiling tests to help some patients safely avoid chemotherapy

The National Institute for Health and Care Excellence (NICE) has today published its final updated guidance on the use of tumour profiling tests...

19 December 2018

"Life-changing" breast cancer tumour profiling tests made available

Responding to NICE final guidance that three tumour profiling tests will be available to guide adjuvant chemotherapy decisions in people with early...

19 December 2018

We respond to research suggesting ‘false positive’ result following a mammogram could indicate increased breast cancer risk

New research published today in the British Journal of Cancer has found that women who experience a ‘false positive’ result following a mammogram are...

19 December 2018

Our CEO responds to the Independent Breast Screening Review report

Responding to the publication of the Independent Breast Screening Review report, announced in May following a serious incident in the screening...

13 December 2018

Perjeta approved in Scotland for certain type of breast cancer

Responding to news that the Scottish Medical Consortium (SMC) has approved the use of pertuzumab (Perjeta) for neo-adjuvant treatment of HER2-...

10 December 2018

We respond to SMC approval of Perjeta for early breast cancer prior to surgery on NHS in Scotland

Breast Cancer Now has welcomed the Scottish Medicines Consortium’s (SMC) decision to approve breast cancer drug Perjeta (pertuzumab) as a new...

10 December 2018

We respond to FDA approval of second drug for patients with BRCA-mutated breast cancer

Earlier this month, the US Food and Drug Administration (FDA) approved the use of a drug called talazoparib (Talzenna), to treat BRCA-mutated locally...

6 December 2018

Scottish breast screening "struggling to cope with demand"

Responding to a parliamentary question answered by Scottish Government, which reveals that there is a backlog in breast screening in some areas of...

5 December 2018

We respond to new report suggesting innovative cancer drugs are taking longer to reach NHS patients

NHS patients are waiting longer for new cancer drugs because of delays in taking them through clinical trials and getting them approved for use, a...

4 December 2018